Ardelyx Q2 Revenue Jumps 33%
Ardelyx ( NASDAQ:ARDX ) , a biopharmaceutical company focused on gastrointestinal and cardiorenal therapeutics, reported its second quarter 2025 earnings on August 4, 2025. The headline news was a major revenue beat, with $97.7 million GAAP revenue reported for Q2 2025 compared to the $81.08 ...
Ardelyx ( ARDX ) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx Announces Changes to the Executive Leadership Team
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer ...
Karyopharm Therapeutics ( KPTI ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Ardelyx ( ARDX ) Q2 Earnings Expected to Decline
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX - Ardelyx ( NASDAQ:ARDX )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ( "Ardelyx" or the "Company" ) ARDX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., June 02, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
Ardelyx to Participate at the Jefferies Global Healthcare Conference ...
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., May 21, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
WALTHAM, Mass., May 21, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ( Nasdaq: ARDX ) , a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President ...
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX - Ardelyx ( NASDAQ:ARDX )
NEW YORK, May 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ( "Ardelyx" or the "Company" ) ARDX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ardelyx Presents Data Supporting IBSRELA® ( tenapanor ) at Digestive Disease Week 2025 Conference - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., May 06, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx Presents Data Supporting IBSRELA® ( tenapanor ) at Digestive Disease Week 2025 Conference
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference ...
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , Advantage Solutions ( NASDAQ:ADV )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Block, Inc. XYZ fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results.
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Apple ( NASDAQ:AAPL ) , Adial Pharmaceuticals ( NASDAQ:ADIL )
Shares of Twilio Inc. TWLO rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Twilio reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $0.94 per share.
Ardelyx ( ARDX ) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -70% and 8.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
WALTHAM, Mass., April 24, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ( Nasdaq: ARDX ) , a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will ...
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
WALTHAM, Mass., April 24, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ( Nasdaq: ARDX ) , a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will ...
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Ardelyx to Report First Quarter 2025 Financial Results on May ...
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time ...
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® ( tenapanor ) to be Presented at the National Kidney Foundation Spring Clinical Meetings - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., April 10, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® ( tenapanor ) at the National Kidney Foundation Spring Clinical Meetings - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., March 31, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy ...
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval ...
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ( Nasdaq: ARDX ) , a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the ...
Ardelyx to Participate in Upcoming Investor Conferences - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ARDX, a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following ...
Ardelyx Tops Estimates as Sales Surge
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.
Ardelyx ( ARDX ) Meets Q4 Earnings Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 4.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales ...
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ( Nasdaq: ARDX ) , a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will ...
BioCryst Pharmaceuticals ( BCRX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx ( ARDX ) Earnings Expected to Grow: Should You Buy?
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Conference call scheduled for 8:00 a.m. Eastern Time Conference call scheduled for 8:00 a.m. Eastern Time ...
Ardelyx ( ARDX ) Moves 16.0% Higher: Will This Strength Last?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities - Ardelyx ( NASDAQ:ARDX )
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million ( unaudited ) Company reaffirms peak U.S. net IBSRELA sales revenue of greater than $1 Billion Company announces peak U.S. net XPHOZAH sales revenue of ...
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million ( unaudited ...
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ARDX, a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will ...
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx Responds to District Court Decision Granting Motion to Dismiss - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc. ARDX, a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today confirmed that Judge Beryl Howell from the U.S.
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients' health at risk ...
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Ardelyx ( ARDX ) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) delivered earnings and revenue surprises of 100% and 13.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx Beats Q3 Sales Estimates, Shares Climb - Ardelyx ( NASDAQ:ARDX )
Ardelyx, Inc. ARDX reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report. The Details: Ardelyx reported quarterly sales of $98.24 million, which beat the analyst consensus estimate of $86.64 million.
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.
Zoetis ( ZTS ) Reports Next Week: Wall Street Expects Earnings Growth
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Ardelyx ( ARDX ) Q3 Earnings Expected to Decline
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Ardelyx ( NASDAQ:ARDX )
NEW YORK, Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ardelyx, Inc.
